UK Markets closed

Adaptimmune Therapeutics plc (ADAP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.1600-0.0700 (-1.65%)
At close: 4:00PM EST
Sign in to post a message.
  • S
    SavageShots
    Does anyone have an idea as to what is driving down the price? Pfizer will be paying $24.99 a share next year.

    Date Open High Low Close* Adj Close** Volume
    Nov 23, 2021 4.0700 4.1399 3.8350 4.1000 4.1000 1,599,498
    Nov 22, 2021 4.2600 4.3100 4.0300 4.1000 4.1000 817,000
    Nov 19, 2021 4.1500 4.3300 4.1200 4.2500 4.2500 674,600
    Nov 18, 2021 4.2500 4.3400 4.0800 4.1600 4.1600 1,176,500
    Nov 17, 2021 4.3410 4.4600 4.2280 4.2300 4.2300 523,600
    Nov 16, 2021 4.3100 4.3950 4.1900 4.3300 4.3300 2,663,000
    Nov 15, 2021 4.6250 4.6900 4.3300 4.3500 4.3500 909,200
    Nov 12, 2021 4.7400 4.7500 4.2500 4.5700 4.5700 1,913,600
    Nov 11, 2021 5.0000 5.1500 4.6050 4.7000 4.7000 2,226,800
    Nov 10, 2021 5.4300 5.5380 5.1600 5.1700 5.1700 710,400
    Nov 09, 2021 5.6400 5.7100 5.4700 5.5100 5.5100 616,100
    Nov 08, 2021 5.6490 5.9500 5.5900 5.6800 5.6800 1,082,700
    Nov 05, 2021 5.3400 5.4800 5.1300 5.4700 5.4700 991,900
    Nov 04, 2021 5.3000 5.4400 5.1000 5.2500 5.2500 427,700
    Nov 03, 2021 5.4800 5.5100 5.2600 5.4700 5.4700 533,400
    Nov 02, 2021 5.4100 5.5500 5.2800 5.4800 5.4800 630,800
    Nov 01, 2021 5.0600 5.4100 5.0600 5.3900 5.3900 471,500
    Oct 29, 2021 5.1600 5.2000 5.0200 5.0700 5.0700 383,500

    Report Date Total Shares Sold Short Dollar Volume Sold Short Change from Previous Report Percentage of Float Shorted Days to Cover Price on Report Date
    10/29/2021 2,950,000 shares $14.96 million -3.9% 2.2% 1.5 $5.07
    10/15/2021 3,070,000 shares $16.36 million -8.4% 2.2% 1.6 $5.33
    9/30/2021 3,350,000 shares $17.32 million -44.9% 2.4% 1.8 $5.17
    9/15/2021 6,080,000 shares $32.83 million +47.9% 4.4% 3.3 $5.40
    8/31/2021 4,110,000 shares $21.25 million +41.2% 3.0% 2.5 $5.17
    8/13/2021 2,910,000 shares $11.61 million +8.2% 2.1% 4 $3.99
  • S
    SavageShots
    https://endpts.com/adaptimmune-says-its-nearly-ready-to-head-to-the-fda-with-tcr-cancer-therapy/

    On 7/13/2015, ADAP reached a high of $20.24, but by 2/21/17 it was trading for $3.95.
    On 10/1/2018, they reached a high of $13.90, but by 11/11/19 it was trading for $0.725
    On 6/1/2020, they reached a high of $11.25, but by 8/2/21 it was trading for $3.49

    At this rate, we should be breaking $0.725 very soon! Who is going to sell their shares that low to the retail investor?

    November 11, 2021 05:04 PM EST R&D
    Adaptimmune says it's (nearly) ready to head to the FDA with TCR cancer therapy
    Max Gelman
    Editor
    Six months after an initial reveal at ASCO, Adaptimmune is back in the limelight with new data Thursday. And the company believes it now has enough to go to regulators for what would be the first-ever TCR therapy.

    The biotech’s afami-cel program put out updated figures Thursday morning with researchers noting as of Sept. 1, 16 of 47 patients saw their tumors shrink while on the experimental treatment. It’s good enough for a 34% overall response rate and, while lower than the May update of 39%, makes Adaptimmune confident enough to say the study will reach its primary endpoint.

    Though the final data cut is expected by the end of the year, “it is mathematically impossible not to meet the primary endpoint,” CEO Adrian Rawcliffe told Endpoints News. Following discussions with the FDA, the biotech had set an 18% response rate as an acceptable threshold to meet the primary.

    “If you assume all future patients will not respond,” he added, “the ones that have yet to be assessed, the trial will still meet the primary endpoint.”

    Despite Rawcliffe’s rosy picture, investors didn’t appear too convinced as Adaptimmune shares $ADAP closed down about 9% in Thursday trading.

    As the trial approaches its end, Rawcliffe noted that the way in which responses are classified may have changed for some patients as independent investigators chimed in, leading to the lower numerical figure. Rawcliffe said it’s the main reason two patients who were previously said to have achieved complete responses are no longer labeled as such.

    Nevertheless, the biotech is prepared to submit its BLA next year once the final data are ready. Rawcliffe described Adaptimmune is “very comfortable” with the whole data package as it stands and highlighted the study’s durability measures. Even though 75% of responders are still receiving treatment, the trial has not reached median duration of response.

    Patients’ response times stretch from about four weeks to more than 65 weeks.

    Adaptimmune had enrolled patients with two types of sarcomas: advanced synovial sarcoma or myxoid/round cell liposarcoma. By each cancer, the ORR was 36% in synovial sarcoma patients and 25% for those with MRCLS. Patients with these cancers generally don’t have many treatment options after chemo, Rawcliffe said, and the five-year mortality rate is around 70-80%.

    Now looking toward its regulatory future, Adaptimmune may likely face similar questions as other companies that have brought forth cell therapies. TCR is similar to CAR-Ts, in that a patient’s cells are removed, re-engineered and replaced to target cancer cells, but TCR goes after a different protein.

    TCRs have historically been met with a lot of skepticism, both from researchers and investors, but this is the second time this week a biotech is touting new data. Immatics revealed an early-stage study that saw eight of 16 patients register an objective response against a range of solid tumor types on Tuesday.

    Rawcliffe himself admitted the company has already been asked about its CMC processes. It’s been at the top of the to-do list in the six months since ASCO, however, and the CEO is confident everything will be in order when the FDA comes knocking.

    “There’s been five cell therapies approved to date, and they all came with challenges of their own,” Rawcliffe said. “Very few of those challenges were related to the clinical data, so anybody who tells you this is easy, or that there is zero risk associated with it, is living in cloud cuckoo land.”
    Six months after an initial reveal at ASCO, Adaptimmune is back in the limelight with new data Thursday. And the company believes it now has enough to go to regulators for what would be the first-ever TCR therapy. The biotech’s afami-cel program put
    Six months after an initial reveal at ASCO, Adaptimmune is back in the limelight with new data Thursday. And the company believes it now has enough to go to regulators for what would be the first-ever TCR therapy. The biotech’s afami-cel program put
    endpts.com
  • A
    Andrew
    Following up on my earlier post regarding similarities with my Trillium stock experience. On April 28th of this year Trillium released a very positive update regarding one of their drug trials as per the following link ….. https://finance.yahoo.com/news/trillium-therapeutics-provides-data-announces-110000323.html

    On April 29th TRIL stock closed at $9.07

    Over the next 4 months the stock price of TRIL went down relentlessly reaching $6.09 on August 23rd at which point Pfizer announced a buyout at a price of $18.50.

    Methinks something similar may be happening with the price of ADAP stock.
    TTI-622 monotherapy shows 33% objective response rate (ORR) in relapsed/refractory (R/R) lymphomas at 0.8-18 mg/kg doses, including 3 new responses (1 Complete Response (CR) + 2 Partial Responses (PRs)) since last data disclosure;TTI-621 monotherapy
    TTI-622 monotherapy shows 33% objective response rate (ORR) in relapsed/refractory (R/R) lymphomas at 0.8-18 mg/kg doses, including 3 new responses (1 Complete Response (CR) + 2 Partial Responses (PRs)) since last data disclosure;TTI-621 monotherapy
    finance.yahoo.com
  • S
    SavageShots
    Based on the lower volumes over the last few days, I'd like to welcome our new retail investors! Many of you are probably hoping for a sky rocketing share price, but be fair warned it is not going to come as soon as you are expecting. Many our seasoned short sellers will be giving you the VIP treatment that includes a Thanksgiving dinner tomorrow but nothing more after that. When the next trading opens, those new retail investors will be escorted to the roller coaster ride of a life time that includes dramatic drops followed by more dramatic drops!!! These next 6 months will test your ability to handle true high risk plays that are followed by low reward. Thank you for joining us today, but it is okay to exit once you are no longer feeling well due to the steady drop of your ADAP holding. Happy Thanksgiving everyone !!!
  • A
    Andrew
    Saw exactly the same behavior with my TRIL position. A concerted effort drove the stock down from over $10 down to under $6. Then magically Pfizer come along with a buyout offer of $18.50. This has all the same hallmarks of a similar strategy. ADAP stock is seeing low ball bids and asks of less than 10 shares at a time to drive the stock price down and shake out all the weak hands. Time to back up the truck and buy.
  • m
    michael
    788,000 block at 1:54 could have cleaned out the persistent seller, and set the stage for a recovery in ADAP. Anyway the increasing volume shows that buyers still exist and those that want to bet against Roche and it's science acumen might be disappointed as usual.
  • J
    James
    The SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year. The ORR per Independent Review was 34% (36% in patients with synovial sarcoma and 25% for patients with MRCLS) and the DCR was 85%. As of the data cut-off, the therapy has shown a favourable benefit risk profile.
  • S
    SD
    Waiting game now?
    Stock was $20+ in 2015- long time waiting for another pop.
    It seemingly feels like the sector is getting rewarded for the "near-end" of trials or approvals as of late.
    A few more months of patience will be rewarded. Game changer imho. I would buy more but I am broke.

    Good luck to all with whatever assets you own.
  • J
    James
    Third Quarter Financial Results and Business Update link to PR, shorturl[DOT]at/krzP6
  • S
    SavageShots
    Maybe tomorrow ADAP will break $4, then $3, then $2 and finally $1! Patiently waiting since IPO day in 2015 to see them bring to market the "Tumor Killer"!
  • U
    UWS44
    Should be $8 on news. Won't be, but should be.
  • D
    David
    Is there a presentation tomorrow morning?
  • k
    kastenz
    They say in black and white, we stand to receive billions in milestone payouts from Genentech (Roche). They're getting to T-cells for cancer quickly. Excellent value anywhere below $1.2 billion, EV only 552, (they have a lot of cash).
  • A
    Andrew
    Fully expect this to be bought out at a price close to $20 or maybe even higher if Roche, Glaxo and Pfizer get into a bidding war.
  • I
    IdGM4
    significant difference in orr compared to previous trial.. won't be approved by fda. they will demand another confirmation trial.
  • S
    SavageShots
    On 7/13/2015, ADAP reached a high of $20.24, but by 2/21/17 it was trading for $3.95.
    On 10/1/2018, they reached a high of $13.90, but by 11/11/19 it was trading for $0.725
    On 6/1/2020, they reached a high of $11.25, but by 8/2/21 it was trading for $3.49

    At this rate, we should be breaking $0.725 very soon! Who is going to sell their shares that low to the retail investor? But first we must break through the $3.37 barrier!!!
  • C
    Curtis
    Long term big gains !
  • F
    FringDook
    added today